Vanguard Global Advisers
TARA icon

Vanguard Global Advisers’s Protara Therapeutics TARA Stock Holding History

Vanguard Global Advisers’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.9K Sell
20,127
-32,472
-62% -$154K ﹤0.01% 2897
2026
Q1 		$274K Buy
+52,599
New +$311K ﹤0.01% 2288

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Vanguard Global Advisers's TARA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Protara Therapeutics (TARA) stake by 62% in Q2 2026, selling an estimated $154K and leaving 20,127 shares worth $76.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2897.

Vanguard Global Advisers first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. The position peaked at $274K in Q1 2026. 118 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Vanguard Global Advisers held 20,127 shares of Protara Therapeutics worth $76.9K as of Q2 2026.
  • Vanguard Global Advisers sold 32,472 Protara Therapeutics shares in Q2 2026, an estimated $154K.
  • Protara Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2897 holding.
  • Vanguard Global Advisers first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Protara Therapeutics position peaked at $274K in Q1 2026.
  • 118 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.